Agilent hp 1100 hplc system

Manufactured by Agilent Technologies

Sourced in United States

The Agilent HP-1100 HPLC system is a high-performance liquid chromatography (HPLC) instrument designed for analytical and preparative chromatographic separations. It features a modular design, allowing for the integration of various components, such as pumps, detectors, and autosamplers, to create a customized solution for diverse analytical applications.

Automatically generated - may contain errors

Lab products found in correlation

Zorbax c8 column, by Agilent Technologies (3 mentions) β ram in us detector, by Agilent Technologies (2 mentions) Ultracel 100k, by Merck Group (1 mentions) Homoarginine, by Merck Group (1 mentions) Zorbax c18 column, by Agilent Technologies (1 mentions) Chemstation software, by Agilent Technologies (1 mentions) Luna c18 column, by Phenomenex (1 mentions)

Spelling variants of this product

Agilent 1100 (550 citations) Agilent 1100 HPLC system (280 citations) HPLC system (280 citations) 1100 HPLC system (268 citations) Agilent 1100 HPLC (179 citations) 1100 HPLC (111 citations) Agilent 1100 system (92 citations) Agilent HPLC system (69 citations) 1100 system (48 citations) HP 1100 HPLC (8 citations)

9 protocols using agilent hp 1100 hplc system

Quantifying Plasma Nitric Oxide Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

We used the HP Agilent 1100 HPLC System (Agilent Technologies Inc., Santa Clara, CA, USA) with fluorescence detection of O-phthalaldehyde/3-mercaptopropionic acid (OPA/3-MPA) derivatives to measure NO-related parameters in the plasma. These parameters include L-Arginine, L-Citrulline (the precursor of L-Arginine), and NO synthase inhibitor asymmetric and symmetric dimethylarginine (ADMA and SDMA). The standards contained 1–100 mM L-Citrulline, 1–100 mM L-Arginine, 0.5–5 mM ADMA, and 0.5–5 mM SDMA. L-Arginine was divided by ADMA plasma levels for calculating the L-Arginine-to-ADMA ratio, a determinant of NO bioavailability [14 (link)].

Hsu C.N., Hou C.Y., Chang-Chien G.P., Lin S., Yang H.W, & Tain Y.L. (2022). Sodium Thiosulfate Improves Hypertension in Rats with Adenine-Induced Chronic Kidney Disease. Antioxidants, 11(1), 147.

+ Open protocol

+ Expand

Quantifying Encapsulation Efficiency and Drug Loading of Nanolipid Carriers

Check if the same lab product or an alternative is used in the 5 most similar protocols

The encapsulating efficiency (EE) and drug loading (DL) capacity were determined indirectly by calculating the amount of non-encapsulated Q present in the aqueous phase of dispersions and applying the following equations:

E E (%) = \frac{{[Q]}_{T o t a l} - {[Q]}_{F r e e}}{{[Q]}_{T o t a l}} \times 100

D L (%) = \frac{{[Q]}_{T o t a l} - {[Q]}_{F r e e}}{{[L i p i d]}_{T o t a l}} \times 100

A total of 500 μL of Q-loaded NLCs (i.e., NLC1 + Q, NLC1 + Q + ω₃, NLC2 + Q, and NLC2 + Q + ω₃) were transferred to Ultracel 100 K centrifugal filter devices (Amicon^® Ultra, Millipore Corporation, Bedford, MA, USA). These filter devices were centrifuged (Labofuge 400 centrifuge, Thermo Scientific Heraeus^®, Cacém, Portugal) at a rcf of 1808× g for 30 min. The amount of [Q]_Free was determined by a high performance liquid chromatography (HPLC) method that was developed based on the methods of Ang et al. [32 (link)] and Vijayakumar et al. [33 (link)]. An HPLC (HP Agilent 1100 HPLC System, Agilent Technologies (Waldbronn, Germany)) equipped with an UV–VIS detector and using an imChem (Voisins le Bretonneux, France) Surf C18 column (5 μm particle size; 150 × 4.6 mm i.d.) was employed. The chromatography was carried out at a flow rate of 1 mL/min under isocratic elution (mobile phase consisting of acetonitrile and 2% v/v acetic acid (pH 2.60) (40%:60% v/v)). All analyses were performed at a 370 nm wavelength and with an injection volume of 20 μL.

Lúcio M., Giannino N., Barreira S., Catita J., Gonçalves H., Ribeiro A., Fernandes E., Carvalho I., Pinho H., Cerqueira F., Biondi M, & Lopes C.M. (2023). Nanostructured Lipid Carriers Enriched Hydrogels for Skin Topical Administration of Quercetin and Omega-3 Fatty Acid. Pharmaceutics, 15(8), 2078.

+ Open protocol

+ Expand

HPLC-based NO Parameter Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols

We used the HP Agilent 1100 HPLC System (Agilent Technologies Inc., Santa Clara, CA, USA) with fluorescence detection using derivatization reaction utilizing O-phthalaldehyde/3-mercaptopropionic acid (OPA/3-MPA) to determine circulating NO-related parameters [37 (link)]. Homoarginine (Sigma-Aldrich, St. Louis, MO, USA) was used as the internal standard.

Hsu C.N., Yu H.R., Chan J.Y., Lee W.C., Wu K.L., Hou C.Y., Chang-Chien G.P., Lin S, & Tain Y.L. (2022). Maternal Acetate Supplementation Reverses Blood Pressure Increase in Male Offspring Induced by Exposure to Minocycline during Pregnancy and Lactation. International Journal of Molecular Sciences, 23(14), 7924.

+ Open protocol

+ Expand

Measurement of NO-related Parameters

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

We used the HP Agilent 1100 HPLC System (Agilent Technologies Inc., Santa Clara, CA, USA) with fluorescence detection of O-phthalaldehyde/3-mercaptopropionic acid (OPA/3-MPA) derivatives to measure NO-related parameters in the plasma as previously described [3 (link)]. These parameters included l-Arginine and NO synthase inhibitor asymmetric and symmetric dimethylarginine (ADMA and SDMA). Standards contained 1–100 mM l-Arginine, 0.5–5 mM ADMA, and 0.5–5 mM SDMA.

Hsu C.N., Hou C.Y., Chang-Chien G.P., Lin S, & Tain Y.L. (2022). Dietary Supplementation with Cysteine during Pregnancy Rescues Maternal Chronic Kidney Disease-Induced Hypertension in Male Rat Offspring: The Impact of Hydrogen Sulfide and Microbiota-Derived Tryptophan Metabolites. Antioxidants, 11(3), 483.

+ Open protocol

+ Expand

HPLC and ITLC Analysis of 99mTcN-MPO

Check if the same lab product or an alternative is used in the 5 most similar protocols

The HPLC (high performance liquid chromatography) method used an Agilent HP-1100 HPLC system (Agilent Technologies, Santa Clara, CA), equipped with a β-ram IN/US detector (Tampa, FL) and Zorbax C₈ column (4.6 mm×250 mm, 300 Å pore size; Agilent Technologies, Santa Clara, CA). The flow rate was 1 mL/min. The mobile phase was isocratic with 30% solvent A (10 mM NH₄OAc buffer, pH = 6.8) and 70% solvent B (methanol) between 0 and 5 min, followed by a gradient from 70% solvent B at 5 min to and 90% solvent B at 20 min. The RCP for ^99mTcN-MPO was calculated as the percentage of peak area over the total area. ITLC (instant thin layer chromatography) used Gelman Sciences silica-gel strips and a 1:1 mixture of acetone/saline (v:v) as eluent. ^99mTcN-MPO and ^99mTcO₄⁻ migrated to solvent front while [^99mTc]colloid stayed at the origin. [^99mTc]colloid was reported as the percentage of radioactivity at the origin over the total radioactivity on each strip.

Zheng Y., Ji S., Tomaselli E, & Liu S. (2014). Development of Kit Formulations for 99mTcN-MPO: A Cationic Radiotracer for Myocardial Perfusion Imaging. Journal of labelled compounds & radiopharmaceuticals, 57(9), 584-592.

+ Open protocol

+ Expand

Radiolabeled RGD Peptide Analysis by HPLC

Check if the same lab product or an alternative is used in the 5 most similar protocols

HPLC Method 1 used a LabAlliance HPLC system (Scientific Systems, Inc., State College, PA) equipped with a UV/vis detector (λ=254 nm) and Zorbax C₁₈ column (9.4 mm × 250 mm, 100 Å pore size; Agilent Technologies, Santa Clara, CA). The flow rate was 2.5 mL/min with a mobile phase being 90% A and 10% B at 0 min to 80% A and 20% B at 5 min, and to 50% A and 50% B at 20 min. The radio-HPLC (Method 2) used an Agilent HP-1100 HPLC system (Agilent Technologies, Santa Clara, CA) equipped with a β-ram IN/US detector (Tampa, FL) and Zorbax C₈ column (4.6 mm × 250 mm, 300 Å pore size; Agilent Technologies, Santa Clara, CA). The flow rate was 1 mL/min. The mobile phase was isocratic for the first 5 min with 90% A (25 mM NH₄OAc, pH = 6.8) and 10% B (acetonitrile), followed by a gradient mobile phase going from 90% A and 10% B at 5 min to 40% A and 60% B at 20 min. The radiochemical purity was reported as the percentage of area for the peak at 15 – 16 min on each radio-HPLC chromatogram of ^99mTc-3P-RGD₂ and ^99mTc-4P-RGD₃. The instant thin layer chromatography (ITLC) used Gelman Sciences silica-gel strips and a 1:1 mixture of acetone and saline as the mobile phase. ^99mTc-3P-RGD₂, ^99mTc-4P-RGD₃ and ^99mTcO₄⁻ migrated to solvent front while [^99mTc]colloid stayed at the origin. [^99mTc]colloid was reported as the percentage of radioactivity at the origin over the total radioactivity on each strip.

Zhao Z.Q., Yang Y., Fang W, & Liu S. (2016). Comparison of Biological Properties of 99mTc-Labeled Cyclic RGD Peptide Trimer and Dimer Useful as SPECT Radiotracers for Tumor Imaging. Nuclear medicine and biology, 43(11), 661-669.

+ Open protocol

+ Expand

HPLC-UV Quantification of Efavirenz in Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma EFV concentrations were determined 12–15 hrs post dose by reverse phase HPLC with UV-detection as previously described [35 (link)] with minor changes. Briefly, the reverse-phase chromatography with column: C18 (150 x 4.6 mm, 5 μm particle size) and UV/VIS detector (DAD) were used. Stock solutions for the calibration standards (0.5μΜ - 60 μM) were prepared using a mixture of acetonitrile (ACN) and water (dH₂O) in the ratio 60:40. The quality control (QC) samples were prepared in the same way as the calibration standards to give final concentrations of 2μΜ (Low QC), 30μΜ (Medium QC) and 50μΜ (High QC). Felodipine was used as the internal standard with a retention time of 6.2 minutes. The mobile phase consisted of a mixture of solutions A and B in a 65:35 proportion. Both solutions contained glacial acetic acid, ACN and 25 mM ammonium acetate buffer in proportions 1:900:100 and 1:100:900, respectively. Plasma proteins were precipitated with ACN before centrifuging. Elution was performed at 1 ml/min giving a retention time for EFV of 5.2 min as detected at UV–VIS 1, 247 nm for a total run time of 10mins. Analysis of chromatograms was performed on the Agilent HP1100 HPLC System and data processing was done using the Chemstation Software (Agilent Technologies, CA, USA).

Dhoro M., Zvada S., Ngara B., Nhachi C., Kadzirange G., Chonzi P, & Masimirembwa C. (2015). CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacology & Toxicology, 16, 4.

+ Open protocol

+ Expand

Quantification of FbiD/CofC-FbiA-coupled Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols

FbiD/CofC-FbiA-coupled activity was monitored in a reaction mixture containing 100 mM HEPES, pH 7.5, 2 mM GTP, 0.1 mM Fo, 5 mM MgCl₂, 1 mM 2-PL or PEP, 1 μM FbiD, and 5 μM FbiA. The reactions were incubated at 37 °C and stopped using 20 mM EDTA at various time points. Separation of F₄₂₀ species was performed on an Agilent HP 1100 HPLC system equipped with photodiode array and fluorescence detectors (Agilent Technologies). Samples were kept at 4 °C, and the injection volume was 20 μL. Samples were separated on a Phenomenex Luna C18 column (150 × 3 mm², 5 μm) with a 0.2 μm in-line filter that was maintained at 30 °C. The mobile phase consisted of 100% methanol (A) and 25 mM sodium acetate buffer, pH 6.0 (B), with a gradient elution at a flow rate of 0.5 mL min⁻¹ and a run time of 30 min. The gradient profile was performed as follows: 0–25 min 95–80% B, 25–26 min 80% B, 26–27 min 95% B, 27–30 min 95% B, and a post-run of 2 min. The wavelengths used for photodiode array were 280 and 420 nm (bandwidth 20 nm) using a reference of 550 nm (bandwidth 50 nm). The wavelengths used for the fluorescence detector were 420 nm (excitation) and 480 nm (emission).

Bashiri G., Antoney J., Jirgis E.N., Shah M.V., Ney B., Copp J., Stuteley S.M., Sreebhavan S., Palmer B., Middleditch M., Tokuriki N., Greening C., Scott C., Baker E.N, & Jackson C.J. (2019). A revised biosynthetic pathway for the cofactor F420 in prokaryotes. Nature Communications, 10, 1558.

+ Open protocol

+ Expand

Routine Analysis of 99mTc(III) Complexes

Check if the same lab product or an alternative is used in the 5 most similar protocols

The radio-HPLC method for routine analysis of ^99mTc(III) complexes [^99mTc(L)(CDO)(CDOH)₂BMe] (L = F, SCN and N₃) used the Agilent HP-1100 HPLC system (Agilent Technologies, Santa Clara, CA) equipped with a β-ram IN/US detector (Tampa, FL) and Zorbax C₈ column (4.6 mm × 250 mm, 300 Å pore size; Agilent Technologies, Santa Clara, CA). The flow rate was 1 mL/min. The mobile phase was isocratic with 30% solvent A (10 mM NH₄OAc buffer, pH = 6.8) and 70% solvent B (methanol) between 0 and 5 min, followed by a gradient from 70% solvent B at 5 min to and 90% solvent B at 15 min and continued till 20 min. The instant thin layer chromatography (ITLC) used Gelman Sciences silica-gel strips and a 1:1 mixture of acetone and saline as the mobile phase. ^99mTc(III) complexes and ^99mTcO⁴⁻ migrated to solvent front while [^99mTc]colloid stayed at the origin. [^99mTc]colloid was reported as the percentage of radioactivity at the origin over the total radioactivity on each strip.

Zheng Y., Ji S., Tomaselli E., Ernest C., Freiji T, & Liu S. (2014). Effect of Co-Ligands on Chemical and Biological Properties of 99mTc(III) Complexes [99mTc(L)(CDO)(CDOH)2BMe] (L = Cl, F, SCN and N3; CDOH2 = Cyclohexanedione Dioxime). Nuclear medicine and biology, 41(10), 813-824.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!